Primary renovascular effects of erythromycin in the rat: Relationship to cyclosporine nephrotoxicity

Amy J. Mccormack, Rose G. Snipes, John J. Dillon, Jia Jin Yang, William F. Finn

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Erythromycin is known to exacerbate cyclosporine nephrotoxicity. This has been attributed to the potential of erythromycin to reduce the hepatic microsomal metabolism and clearance of cyclosporine. Erythromycin may also be nephrotoxic. We tested the hypothesis that erythromycin may have direct effects on the renal vasculature which are additive or synergistic with the effects of cyclosporine. Sprague-Dawley rats were administered graded doses of either erythromycin, 2.5, 5, 7.5, and 10 mg/kg BW/min i. v. over consecutive 10-min intervals; cyclosporine, 1,2, 3, and 4 mg/kg BW/min i.v. over consecutive 10-min intervals; or both drugs simultaneously. In separate experiments, identical doses of erythromycin or cyclosporine were infused intravenously following acute unilateral renal denerva-tion. Infusion of erythromycin led to an initial decline in arterial blood pressure whereas infusion of cyclosporine resulted in a dose-related increase in arterial blood pressure. Despite these different systemic effects, each drug alone produced a striking decrease in renal blood flow. This effect was more pronounced when the drugs were infused concomitantly. The reduction in renal blood flow occurred in an additive manner as a direct consequence of increased renal vascular resistance. Prior renal denervation did not modify the response to either erythromycin or cyclosporine. These results demonstrate that cyclosporine-induced vasoconstriction is exacerbated by erythromycin and suggest that the decline in renal function observed in patients coadministered these drugs may be due in part to additive renovascular toxicity.

Original languageEnglish (US)
Pages (from-to)241-248
Number of pages8
JournalRenal Failure
Volume12
Issue number4
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

Erythromycin
Cyclosporine
Kidney
Renal Circulation
Pharmaceutical Preparations
Arterial Pressure
Denervation
Vasoconstriction
Vascular Resistance
Sprague Dawley Rats
Liver

ASJC Scopus subject areas

  • Nephrology
  • Critical Care and Intensive Care Medicine

Cite this

Mccormack, A. J., Snipes, R. G., Dillon, J. J., Yang, J. J., & Finn, W. F. (1990). Primary renovascular effects of erythromycin in the rat: Relationship to cyclosporine nephrotoxicity. Renal Failure, 12(4), 241-248. https://doi.org/10.3109/08860229009060731

Primary renovascular effects of erythromycin in the rat : Relationship to cyclosporine nephrotoxicity. / Mccormack, Amy J.; Snipes, Rose G.; Dillon, John J.; Yang, Jia Jin; Finn, William F.

In: Renal Failure, Vol. 12, No. 4, 1990, p. 241-248.

Research output: Contribution to journalArticle

Mccormack, Amy J. ; Snipes, Rose G. ; Dillon, John J. ; Yang, Jia Jin ; Finn, William F. / Primary renovascular effects of erythromycin in the rat : Relationship to cyclosporine nephrotoxicity. In: Renal Failure. 1990 ; Vol. 12, No. 4. pp. 241-248.
@article{ee357f4e9fa6466c9a0cd146f403dcfc,
title = "Primary renovascular effects of erythromycin in the rat: Relationship to cyclosporine nephrotoxicity",
abstract = "Erythromycin is known to exacerbate cyclosporine nephrotoxicity. This has been attributed to the potential of erythromycin to reduce the hepatic microsomal metabolism and clearance of cyclosporine. Erythromycin may also be nephrotoxic. We tested the hypothesis that erythromycin may have direct effects on the renal vasculature which are additive or synergistic with the effects of cyclosporine. Sprague-Dawley rats were administered graded doses of either erythromycin, 2.5, 5, 7.5, and 10 mg/kg BW/min i. v. over consecutive 10-min intervals; cyclosporine, 1,2, 3, and 4 mg/kg BW/min i.v. over consecutive 10-min intervals; or both drugs simultaneously. In separate experiments, identical doses of erythromycin or cyclosporine were infused intravenously following acute unilateral renal denerva-tion. Infusion of erythromycin led to an initial decline in arterial blood pressure whereas infusion of cyclosporine resulted in a dose-related increase in arterial blood pressure. Despite these different systemic effects, each drug alone produced a striking decrease in renal blood flow. This effect was more pronounced when the drugs were infused concomitantly. The reduction in renal blood flow occurred in an additive manner as a direct consequence of increased renal vascular resistance. Prior renal denervation did not modify the response to either erythromycin or cyclosporine. These results demonstrate that cyclosporine-induced vasoconstriction is exacerbated by erythromycin and suggest that the decline in renal function observed in patients coadministered these drugs may be due in part to additive renovascular toxicity.",
author = "Mccormack, {Amy J.} and Snipes, {Rose G.} and Dillon, {John J.} and Yang, {Jia Jin} and Finn, {William F.}",
year = "1990",
doi = "10.3109/08860229009060731",
language = "English (US)",
volume = "12",
pages = "241--248",
journal = "Renal Failure",
issn = "0886-022X",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Primary renovascular effects of erythromycin in the rat

T2 - Relationship to cyclosporine nephrotoxicity

AU - Mccormack, Amy J.

AU - Snipes, Rose G.

AU - Dillon, John J.

AU - Yang, Jia Jin

AU - Finn, William F.

PY - 1990

Y1 - 1990

N2 - Erythromycin is known to exacerbate cyclosporine nephrotoxicity. This has been attributed to the potential of erythromycin to reduce the hepatic microsomal metabolism and clearance of cyclosporine. Erythromycin may also be nephrotoxic. We tested the hypothesis that erythromycin may have direct effects on the renal vasculature which are additive or synergistic with the effects of cyclosporine. Sprague-Dawley rats were administered graded doses of either erythromycin, 2.5, 5, 7.5, and 10 mg/kg BW/min i. v. over consecutive 10-min intervals; cyclosporine, 1,2, 3, and 4 mg/kg BW/min i.v. over consecutive 10-min intervals; or both drugs simultaneously. In separate experiments, identical doses of erythromycin or cyclosporine were infused intravenously following acute unilateral renal denerva-tion. Infusion of erythromycin led to an initial decline in arterial blood pressure whereas infusion of cyclosporine resulted in a dose-related increase in arterial blood pressure. Despite these different systemic effects, each drug alone produced a striking decrease in renal blood flow. This effect was more pronounced when the drugs were infused concomitantly. The reduction in renal blood flow occurred in an additive manner as a direct consequence of increased renal vascular resistance. Prior renal denervation did not modify the response to either erythromycin or cyclosporine. These results demonstrate that cyclosporine-induced vasoconstriction is exacerbated by erythromycin and suggest that the decline in renal function observed in patients coadministered these drugs may be due in part to additive renovascular toxicity.

AB - Erythromycin is known to exacerbate cyclosporine nephrotoxicity. This has been attributed to the potential of erythromycin to reduce the hepatic microsomal metabolism and clearance of cyclosporine. Erythromycin may also be nephrotoxic. We tested the hypothesis that erythromycin may have direct effects on the renal vasculature which are additive or synergistic with the effects of cyclosporine. Sprague-Dawley rats were administered graded doses of either erythromycin, 2.5, 5, 7.5, and 10 mg/kg BW/min i. v. over consecutive 10-min intervals; cyclosporine, 1,2, 3, and 4 mg/kg BW/min i.v. over consecutive 10-min intervals; or both drugs simultaneously. In separate experiments, identical doses of erythromycin or cyclosporine were infused intravenously following acute unilateral renal denerva-tion. Infusion of erythromycin led to an initial decline in arterial blood pressure whereas infusion of cyclosporine resulted in a dose-related increase in arterial blood pressure. Despite these different systemic effects, each drug alone produced a striking decrease in renal blood flow. This effect was more pronounced when the drugs were infused concomitantly. The reduction in renal blood flow occurred in an additive manner as a direct consequence of increased renal vascular resistance. Prior renal denervation did not modify the response to either erythromycin or cyclosporine. These results demonstrate that cyclosporine-induced vasoconstriction is exacerbated by erythromycin and suggest that the decline in renal function observed in patients coadministered these drugs may be due in part to additive renovascular toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0025559642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025559642&partnerID=8YFLogxK

U2 - 10.3109/08860229009060731

DO - 10.3109/08860229009060731

M3 - Article

C2 - 2100828

AN - SCOPUS:0025559642

VL - 12

SP - 241

EP - 248

JO - Renal Failure

JF - Renal Failure

SN - 0886-022X

IS - 4

ER -